Know Cancer

forgot password

A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias

Phase 1
18 Years
Open (Enrolling)
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, High-risk Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Advanced Myelofibrosis

Thank you

Trial Information

A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias

Tumor hypoxia has been associated with resistance to chemotherapy and radiotherapy (Brown et
al, 2004; Boyle 2006). TH-302, a hypoxia activated prodrug (HAP), exploits the hypoxic
nature of tumors while having little or no effect on normal tissue. TH-302 belongs to a
class of alkylating agents called oxazaphosphorines which have major experimental and
clinical activity (Brock 1989). Since TH-302 is selectively targeted to the hypoxic
microenvironment, this agent may represent an improvement over other agents in this class.
Preclinical data support the hypothesis that TH-302 targets hypoxic regions of tumors and
also is able to kill other tumor cells in normoxic regions as a result of cytotoxin
diffusion, leading to significant effects on tumor growth. Preclinical data has shown that
TH-302 has anti-tumor activity in multiple myeloma cells in vivo and in vitro.

Additional preclinical data demonstrated the marked expansion of the hypoxic bone marrow
areas in diseased mice with ALL. These results suggest that this agent may be useful in
treating advanced leukemias. The drug is stable in plasma and liver, does not appear to be
at risk for drug-drug interactions, and has mild, reversible toxicities. In this
dose-escalation study, patients with advanced leukemias will receive infusions of TH-302 to
determine the maximum tolerated dose.

Inclusion Criteria:

- At least 18 years of age.

- Ability to understand the purposes and risks of the study and has signed a written
informed consent form approved by the investigator's IRB/Ethics Committee.

- Relapsed/refractory leukemias for which no standard therapy options are anticipated
to result in a durable remission.

- Acute myelogenous leukemia (AML) by WHO classification relapsed or refractory to
standard chemotherapy; unsuitable for standard chemotherapy or unwilling to undergo
standard chemotherapy.

- Acute lymphoblastic leukemia (ALL) relapsed or refractory to standard chemotherapy;
unsuitable for standard chemotherapy or unwilling to undergo standard chemotherapy.
Philadelphia chromosome (Ph) positive ALL eligible if failed prior tyrosinekinase
inhibitor therapy.

- Chronic myelogenous leukemia (CML) in accelerated or blast phase failing prior
tyrosine kinase-containing therapy

- High-risk myelodysplastic syndrome (MDS) [i.e. refractory anemia with excess blasts
(RAEB-1 or RAEB-2) by WHO classification] or chronic myelomonocytic leukemia (CMML)
with >5% marrow blasts, relapsed or refractory to standard therapy

- Chronic lymphocytic leukemia (CLL) relapsed or refractory to standard therapy, not
eligible for protocols of higher priority

- Advanced myelofibrosis (MF) resistant or refractory to standard therapy; or untreated
with one of following features (1) hemoglobin < 10 g/dL, (2) platelet count < 100 x
109/L, WBC < 4 or > 30 x 109/L, or splenomegaly ≥ 10 cm below left costal margin

- Age > 60 years with AML not candidates for or have refused standard chemotherapy,
excluding subjects with acute promyelocytic leukemia (APL) or with favorable
cytogenetic abnormalities [inv16, t(8;21)].

- ECOG performance status of less than or equal to 3

- Adequate organ function as indicated by the following laboratory assessments
performed within 14 days prior to the first dose of study drug:

- Total bilirubin ≤ 1.5 times upper limit of normal (x ULN) (≤ 3 x ULN if due to
leukemic involvement or Gilbert's syndrome).

- Aspartate aminotransferase or alanine aminotransferase ≤ 2.5 x ULN (≤ 5.0 x ULN if
due to leukemic involvement)

- Serum creatinine ≤ 1.5 x ULN.

- All women of childbearing potential must have a negative serum pregnancy test and
women and men subjects must agree to use effective means of contraception (surgical
sterilization or the use or barrier contraception with either a condom or diaphragm
in conjunction with spermicidal gel or an IUD) with their partner from entry into the
study through 6 months after the last dose

Exclusion Criteria:

- New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial
infarction within 6 months prior to Day 1, or unstable arrhythmia

- Seizure disorders requiring anticonvulsant therapy

- Severe chronic obstructive pulmonary disease with hypoxemia or in the opinion of the
investigator any physiological state leading to hypoxemia

- Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without
complete recovery

- Active uncontrolled infection

- Systemic chemotherapy (with the exception of hydroxyurea and/or steroids) within 14
days (or within 5 half-lives for an investigational agent) prior to first dose of
study drug, unless there is evidence of rapidly progressive disease. Concurrent
therapy for CNS prophylaxis or continuation of therapy for controlled CNS disease is

- Known active infection with HIV, hepatitis B, or hepatitis C

- Patients who have exhibited allergic reactions to a similar structural compound,
biological agent, or formulation (containing solutol and/or propylene glycol)

- Females who are pregnant or breast-feeding

- Concomitant disease or condition that could interfere with the conduct of the study,
or that would, in the opinion of the investigator, pose an unacceptable risk to the
subject in this study

- Unwillingness or inability to comply with the study protocol for any reason

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the maximum tolerated dose of TH-302

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Marina Konopleva, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

June 2010

Completion Date:

June 2013

Related Keywords:

  • Acute Myelogenous Leukemia
  • Acute Lymphoblastic Leukemia
  • Chronic Myelogenous Leukemia
  • High-risk Myelodysplastic Syndrome
  • Chronic Lymphocytic Leukemia
  • Advanced Myelofibrosis
  • Advanced Leukemias
  • Relapsed/Refractory Leukemias
  • AML
  • ALL
  • CML
  • MDS
  • CLL
  • MF
  • Primary Myelofibrosis
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Myelodysplastic Syndromes
  • Preleukemia
  • Anoxia



University of Texas M.D. Anderson Cancer CenterHouston, Texas  77030